Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Trial Profile

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
  • Indications Ovarian cancer
  • Focus Diagnostic use; Registrational
  • Sponsors On Target Laboratories
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 08 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Aug 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top